Table 1 Evaluation of the markers using the discovery set with 12 non-lepidic AD and three PDSCC patients

AD markers

(Marker status)

Sensitivity

Specificity

PPV

NPV

Accuracy

(subtype)

AD

SCC

AD

SCC

(95 % CI†)

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

ST6GALNAC1*

8

0

4

3

0.667 (0.349–0.901)

1.000 (0.292–1.000)

1.000 (0.631–1.000)

0.429 (0.099–0.816)

0.733 (0.099–0.816)

TTF-1

5

0

7

3

0.417 (0.152–0.723)

1.000 (0.292–1.000)

1.000 (0.478–1.000)

0.300 (0.067–0.652)

0.533 (0.266–0.787)

napsin A

2

0

10

3

0.167 (0.021–0.484)

1.000 (0.292–1.000)

1.000 (0.158–1.000)

0.231 (0.050–0.538)

0.333 (0.118–0.616)

SCC markers

(Marker status)

Sensitivity

Specificity

PPV

NPV

Accuracy

(subtype)

SCC

AD

SCC

AD

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

SPATS2*

2

0

1

12

0.667 (0.094–0.992)

1.000 (0.735–1.000)

1.000 (0.158–1.000)

0.923 (0.640–0.998)

0.933 (0.681–0.998)

CK5

1

0

2

12

0.333 (0.008–0.906)

1.000 (0.735–1.000)

1.000 (0.025–1.000)

0.857 (0.572–0.982)

0.867 (0.595–0.983)

DSG3

0

0

3

12

0.000

(0.000–0.708)

1.000

(0.735–1.000)

N.A.

0.800 (0.519–0.957)

0.800 (0.519–0.957)

p40

1

0

2

12

0.333

(0.008–0.906)

1.000

(0.735–1.000)

1.000

(0.025–1.000)

0.857

(0.572–0.982)

0.867 (0.595–0.983)

CK6

0

0

3

12

0.000 (0.000–0.708)

1.000 (0.735–1.000)

N.A.

0.800 (0.519–0.957)

0.800 (0.519–0.957)